Morinamide

Morinamide
Clinical data
Trade names	Piazolina
AHFS/Drugs.com	International Drug Names
ATC code	J04AK04 ( WHO );
Legal status
Legal status	BR: Class A1 (Narcotic drugs);
Identifiers
	IUPAC name N-(morpholin-4-ylmethyl)pyrazine-2-carboxamide;
CAS Number	952-54-5 ;
PubChem CID	70374 ;
ChemSpider	63555 ;
UNII	8CFL28PA3W ;
KEGG	D07248 ;
CompTox Dashboard (EPA)	DTXSID4046159 ;
ECHA InfoCard	100.012.237
Chemical and physical data
Formula	C10H14N4O2
Molar mass	222.248 g·mol−1
3D model (JSmol)	Interactive image ;
	SMILES O=C(NCN1CCOCC1)c1cnccn1;
	InChI InChI=1S/C10H14N4O2/c15-10(9-7-11-1-2-12-9)13-8-14-3-5-16-6-4-14/h1-2,7H,3-6,8H2,(H,13,15); Key:GVTLAVKAVSKBKK-UHFFFAOYSA-N;
	(verify)

Last updated August 22, 2025

Morinamide (or morphazinamide, or morinamid) is a drug used in the treatment of tuberculosis.^[2] Although morphazinamide is metabolized to pyrazinamide within the body,^[3] the drug itself has intrinsic in vitro activity.^[4]

References

↑ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
↑ Bonanni G, Ciccariello M, Mancini P, Pace V, Sagliaschi G (1993). "Concomitant ceco-appendicular and urinary tuberculosis. Description of two rare cases: physiopathological and diagnostic remarks". Riv Eur Sci Med Farmacol. 15 (3–4): 171–174. PMID 7761665.
↑ Trnka L, Kuška J, Havel A (1964). "Comparison of the Antituberculous Activity of Morphazinamide and Pyrazinamide on Chronic Experimental Tuberculosis. I. The Antimycobacterial Efficacy made in vitro and in vivo". Chemotherapia. 9 (3): 158–167. doi:10.1159/000220356.
↑ Carrada Bravo T, Ellard G, Mitchison D, Horsfall P (1975). "Reappraisal of the activity of morphazinamide against M. tuberculosis". Tubercle. 56 (3): 211–217. doi:10.1016/0041-3879(75)90054-9.

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[1] Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.

[Bonanni_1993-2] Bonanni G, Ciccariello M, Mancini P, Pace V, Sagliaschi G (1993). "Concomitant ceco-appendicular and urinary tuberculosis. Description of two rare cases: physiopathological and diagnostic remarks". Riv Eur Sci Med Farmacol. 15 (3–4): 171–174. PMID 7761665.

[3] Trnka L, Kuška J, Havel A (1964). "Comparison of the Antituberculous Activity of Morphazinamide and Pyrazinamide on Chronic Experimental Tuberculosis. I. The Antimycobacterial Efficacy made in vitro and in vivo". Chemotherapia. 9 (3): 158–167. doi:10.1159/000220356.

[4] Carrada Bravo T, Ellard G, Mitchison D, Horsfall P (1975). "Reappraisal of the activity of morphazinamide against M. tuberculosis". Tubercle. 56 (3): 211–217. doi:10.1016/0041-3879(75)90054-9.

[1]

[2]

[3]

[4]